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Abstract
Background: All women are potentially at risk of developing cervical cancer at some point in their life, yet it is
avoidable cause of death among women in Sub- Saharan Africa with a world incidence of 530,000 every year. It is
the 4th commonest cancer affecting women worldwide with over 260,000 deaths reported in 2012. Low resource
settings account for over 75% of the global cervical cancer burden. Uptake of HPV vaccination is limited in the
developing world. WHO recommended that 2 doses of HPV vaccine could be given to young girls, based on
studies in developed countries. However in Africa high rates of infections like malaria and worms can affect
immune responses to vaccines, therefore three doses may still be necessary. The aim of this study was to identify
barriers and facilitators associated with uptake of HPV vaccine.
Methods: A cross-sectional survey was conducted at Eldoret, Kenya involving 3000 girls aged 9 to 14 years from 40
schools. Parents/guardians gave consent through a questionnaire.
Results: Of all 3083 the school girls 93.8% had received childhood vaccines and 63.8% had a second HPV dose, and 39.
1% had a third dose. Administration of second dose and HPV knowledge were both strong predictors of completion of
the third dose. Distance to the hospital was a statistically significant risk factor for non-completion (P: 0.01).
Conclusions: Distance to vaccination centers requires a more innovative vaccine-delivery strategy and education of
parents/guardians on cervical screening to increase attainment of the HPV vaccination.
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Background
All women are potentially at risk of developing cervical
cancer at some point in their life, yet it is avoidable
cause of death among women in Sub- Saharan Africa
with a world incidence of 530,000 every year. It is the
4th commonest cancer affecting women worldwide with
over 260,000 deaths reported in 2012. Low resource
settings account for over 75% of the global cervical
cancer burden [1].
Cervical cancer remains the most common cancer in
Eastern and Central Africa with an estimated with
estimated age standardized rates (ASRs) of 42.7 and 30.6
respectively compared with 2–5 in Western Europe and
Australia. Mortality is highest in Eastern Africa at 27 per
10,000 compared to less than 2 per 100,000 in Western
Asia/Europe, Australia and New Zealand [1].
Among the Eastern African countries, Kenya has a
high cervical cancer burden which is the leading cause
of cancer deaths in women of reproductive age and the
2nd most frequent cancer among women in Kenya. The
incidence of cervical cancer cases in Kenya is estimated
at close to 2500 with annual deaths close to just over
1500 with an average life lost estimated at 25 years. The
* Correspondence: mabeya4@gmail.com; icrh@ugent.be
1Moi University, Eldoret, Kenya
2International Center of Reproductive Health, Ghent University, De Pintelaan
185 P3, 9000 Ghent, Belgium
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mabeya et al. BMC Cancer  (2018) 18:557 
https://doi.org/10.1186/s12885-018-4382-x
incidence is projected to double by the year 2025 if no
efforts are put to mitigate the increment. Secondary pre-
vention for women in reproductive age is only 3% com-
pared with 40–70% in high resource countries [2–6].
HPV vaccination as a primary prevention method is
supplemented by screening later in life. This is because
vaccines do not protect against all high-risk and poten-
tial high-risk HPV types. Vaccines to prevent cervical
cancers are now available. The quadrivalent (Gardasil 4)
vaccine protecting against human papilloma virus (HPV)
types 16/18/6/11 and the bivalent (Cervirax) vaccine
protecting against infection with HPV-16/18 were both
originally used as a three dose schedule. A third vaccine,
the nonavalent HPV (Gardasil 9) vaccine protecting
against HPV types 16/18/6/11/31/33/45/52/58 has been
approved by Food and Drug Administration (FDA) in
2014 in the USA [7]. The cost and logistical difficulties
and cost in resource-constraint settings has delayed or
slowed implementation of the original three-dose vac-
cine regimen. GAVI Alliance supported HPV vaccination
in 2011 and if less than three dose schedule is adopted
in these countries, there will be an increase the imple-
mentation of HPV vaccination programs in resource-
constraint countries [4, 7]. Three vaccines are now being
marketed in many countries as primary prevention inter-
vention tool. HPV 16 and 18 are responsible for approxi-
mately 70% of cervical cancer cases globally. Gardasil
and Nonavalent also prevent anogenital warts that are
caused by HPV 6 and 11 [8].
World Health Organisation has recommended offering
HPV vaccination to girls at ages 9–13 and Kenya has de-
veloped a comprehensive strategy to address cervical
cancer, which includes rollout of HPV vaccination
among girls, with the purpose of vaccinating girls naïve
to the targeted types. This roll out of HPV vaccine
among girls naïve to the targeted types, is akin to the
one which took place in Rwanda, Uganda, Cameroon,
Tanzania, Lesotho and South Africa, which have intro-
duced HPV vaccine to prevent cervical cancer through
school-based programme [5–7, 9, 10, 11].
WHO has recommended bivalent or quadrivalent vac-
cine in the 2-dose schedule with a 6-month interval be-
tween doses for females less than 15 years old, including
females 15 years or older at the time of the second dose
based on available studies, before the females become
sexually active. A third dose is recommended at least
6 months after the first dose, if the interval between the
two doses is shorter than 5 months and for 15 years old or
more who are known to be immunocompromised and/or
HIV-infected or are already sexually active. This 2 dose
recommendation will lead to cost saving and other logistic
problems of delivering the vaccine and compliance [2, 7].
Education and knowledge by health personnel and
parents/guardians about cervical cancer, HPV and HPV
vaccines is necessary for vaccine uptake and hence en-
hanced primary prevention of cervical cancer [12–15].
An HPV immunization program must also consider the
unique challenges that HPV vaccination implementation
faces, including a recommended schedule consisting of 2
doses for 9 to 14 year old girls and 3 doses for those
above 15 years and if they are immunocompromised. So
far, there is no published research from Kenya on risk
factors for partial HPV regimen administration.
This study sought to explore barriers and facilitators
that undermine or promote adherence to 3 doses HPV
vaccine in a malaria and helminthic endemic western
Kenya and explore policy implications for HPV vaccine
introduction. Watson-Jones et al. in their attitudes and
access to HPV vaccination among Maasai pastoralists
and slum dwellers study found challenges to an HPV
vaccination programme included early age of sex and
marriage, lack of parental support, school absenteeism
and drop-out, population mobility and distance from
services. Despite little prior knowledge of cervical cancer
and HPV, and school-based vaccination, communities
were interested in receiving HPV vaccination. Adequate
social mobilization supplemented by out-reach activities,
were considered important facilitating factors to achieve
high coverage [16].
HPV vaccines in populations whose immunological
system may be challenged by multiple co-infections such
as malaria and helminth infections are needed measure
long term protection and advice on booster doses. Stud-
ies have shown that malaria and helminth infections
have an effect on long term vaccine responses and hence
more research is needed [17, 18].
In 2007 GAP reached more than 445,000 girls in 21
countries and several have implemented a national
vaccination program. The burden of cervical cancer re-
mains a big problem in developing world and the GAP
initiative through the vaccine delivery will continue to play
a valuable role as countries consider large-scale imple-
mentation. The demonstration programs and comprehen-
sive analysis of the vaccine delivery has been published in
BMC Public Health in May 2012 [19, 20].
In sub-Saharan Africa, many countries are considering the
implementation of HPV vaccination. These countries have a
high prevalence of endemic malaria and helminth infections
that can act as immunological modulators and impact re-
sponses to standard immunizations. These infections can
impact immune responses to vaccinations [21–27].
Sub-Saharan Africa except South Africa has high
incidences of malaria. In Kenya, malaria remains a major
cause of morbidity and mortality with more than 70% of
the population at risk of the disease (MOH 2014). More
than four million cases of malaria are reported annually
in Kenya. A 5.1% mortality ratehas been reported among
patients admitted with severe malaria. The malaria
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burden in Kenya is not homogeneous. Western Kenya,
areas around Lake Victoria and on the cost present the
highest risk [28–30].
A high HPV immunogenicity regardless of the pres-
ence of malaria and helminth infections among young
girls and women in Tanzania study was found. There
was some evidence of enhanced antibody titres to HPV
vaccine genotypes in participants with malaria parasit-
aemia. Additional research on the impact of parasitic in-
fection on the long-term duration of protection from
HPV vaccines is warranted [31].
There is a paucity of information on the association
between malaria and/or helminthic disease and cervical
disease progression. The way malaria and helminths
affect the immune response to HPV vaccine long term
protection needs to be investigated. Studies should ex-
plore differences between levels of HPV 16/18 antibodies
after administration of the vaccine among girls exposed
to malaria/and or helminthic infections [32].
Methods
Promotion
Through the GARDASIL Access Program (GAP), the Moi
Referral and Teaching Hospital (MTRH) was granted
9600 doses of the quadrivalent vaccine to administer to
young girls in Eldoret, Kenya. MTRH is Kenya’s second
largest referral hospital with a bed capacity of 550 of
which 100 are in reproductive health wards, with a service
population of 13 million people. It is located in Eldoret
town about 325 km from Nairobi in Western part of
Kenya. It is a teaching hospital for both undergraduate
and post graduate students from Moi University.
Eldoret is a principal city in western Kenya. It also
serves as the capital of Uasin Gishu County. Lying south
of the Cherangani Hills, the local elevation varies from
about 2100–2700 (7000–9000 ft). The population was
289,380 in the 2009 census and it is currently the fastest
growing town in Kenya.
Eldoret experiences highland malaria transmission if
temperatures become warm and rainfall encourages
mosquito breeding. Residents of Eldoret do not develop
immunity and suffer much more serious illness than
their lowland neighbours.
Promotion of the program was restricted to a number
of randomly selected government primary schools, al-
though other girls from the community were not refused
if appeared at the vaccination site. A hospital-based vac-
cination was chosen to reduce the costs of the program.
The vaccines were offered to girls of age 9 to 14 years
old, from ten primary schools in Eldoret Municipality.
These schools were randomly selected until a total of
about 4000 eligible girls was reached, expecting a cover-
age of around 75% (3000/4000). Permission to roll out
the vaccination was given from the County Director of
Education who in turn instructed the head teachers of
involved schools. A training of trainers (TOT) process
was set in motion, with teachers first being trained by
health staff and through the provision of leaflets the
teachers were asked to instruct students and parents/
guardians on HPV vaccination and cervical cancer.
Vaccination took place from May 2012 to March 2013.
After a signed consent was obtained from the parent/
guardian, nurses vaccinated the girls. A vaccination card
with a next appointment was given upon the first and
second dose. Additionally, caregivers who failed to show
up on the schedule day were given a reminder by nurses
about the second and third dose. Due to a low response
during the first 3 months of the program, other schools
in the County, government and private, were also invited
to participate from August 2012 onwards through post-
ers in the hospital and radio. In September 2012, the
program stopped administering the first dose after
reaching 3000 girls with a view to guaranteeing sufficient
vaccines for the remaining doses.
The survey
This was done before administration of the vaccine. The
questionnaire consisted of two parts. The first part col-
lected information on sociodemographic characteristics,
including religion and age of school girls. The second
part consisted of questions regarding the guardian’s
knowledge of HPV, Pap smear knowledge and whether
the female guardian/spouse had undergone a Pap smear
test. The survey used in this study was designed by pub-
lic health specialists and physicians. Data was collected
from 22/04/2012 to 23/04/2014 by data collection team.
The survey was pilot-tested by for comprehensibility
before study commencement.
Interviewers administered questionnaires in English,
and verbal interpretation in Swahili based on the partici-
pant’s request.
Data analysis
Following data checking and cleaning, analysis was
undertaken using STATA version 12. Corporation, Col-
lege Station, TX, USA. In order to assess whether a me-
dian or mean should be given for continuous variables, a
Shapiro-Wilk test at an alpha level of 5% was performed
to assess whether the variable was parametric. We
checked to see whether the missing data (< 5%) was
missing completely at Random by performing the Little’s
MCAR test. Prob> chi-square = 0.5472 so indicating that
the data missing is completely at random and is unlikely
to have altered our results and multiple imputation is
not required.
Dates for second dose, third dose, Pap smear under-
taken, HPV knowledge was dichotomized into the two
categories, yes and no. Google maps were used to
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calculate distance from School to vaccination center.
Distance to health centre in kilometres and age were
both used as a continuous variable and the non-
parametric Mann Whitney rank sum test was performed
as it could not be assumed that the continuous variables
were normally distributed. Bivariate logistic regression
was used to measure the strength of the association,
with the dependent variable being the number of dose.
Statistical analyses were performed using ‘svy’command
to account for clustering in making variance estimates,
with school being the primary sampling unit.
A statistical test was considered significant if the
p-value is 0.05 and borderline significant it was be-
tween 0.06 and 0.1.
Results
Population characteristics
The median age range of schoolgirls whose caregivers
were interviewed was 12 (IQR: 10–13), of which, 2853
(99.2%) was Christian and 22 (0.8%) Muslim. 843 (28.
1%) had a male parent, 2154 (71.8%) had a female parent
and 3 (0.1%) had both. 786 (27%) of parents/guardian
had no knowledge of Pap tests. 307(14.4%) of all female
guardians underwent a Pap test; 824 (27.2%) of parents/
guardians had knowledge of HPV. Of all the school girls
eligible for this study 2808(93.8%) had childhood vac-
cines and 1933(63.8%) had second HPV dose, and 1182
(39.1%) had a third dose. The mean time elapsed
between the second HPV vaccine and the first vaccine
was 32.5 days (SD 22.7), the third HPV vaccine and the
second vaccine 148 days (SD: 17.5). The median time
elapsed between the first HPV vaccine dose and the
third HPV vaccine dose was 175 days (IQR: 168–182)
(see Table 1).
Barriers and facilitators of HPV vaccine uptake
Administration of second dose of HPV and HPV know-
ledge were both strong predictors of taking the third dose
of HPV vaccine (OR: 61.1; p < 0.001; 95% CI = 40.9–91.0)
and (OR: 1.2;p = 0.008; 95%CI 1.1–1.5) respectively. A
Mann Whitney test revealed that distance to health facility
was a statistically significant barrier (p.0.01).
A 14% higher odds of administration of all three doses
was found for girls who had a male guardian (p = 0.04;
CI: 1.0–1.3). A marginal association was observed be-
tween Pap test knowledge of the guardian and third
HPV vaccine (OR: 1.2; p:0.08; CI:1.0–1.4).
No statistically significant risk factors were observed
for childhood vaccine (OR: 1.2; p: 0.4; CI: 0.8–1.6), reli-
gion (OR:1.1; p: 0.9; CI: 0.5–2.5) and female guardian
who had a Pap test OR 0.9; p:0.6; CI:0.7–1.2. A Mann
Whitney rank sum test did not reveal a significant differ-
ence in age medians between those who had the third HPV
vaccine and those who did not. (p: 0.1). (See Table 2).
Discussion
Three studies have been conducted in Kenya on actual
HPV vaccination, our study and Ministry of Health
GAVI HPV demonstration project in Kitui Kenya (2015).
Table 1 Population characteristics
Population characteristics Number Percentage and Confidence Interval
Age 12 (IQR: 10–13)
Religion
Christian 2853/2875 99.20% (95%CI: 99.0–99.5%)
Muslim 22/ 2875 0.80% (95%CI .0.5–1.2)
Caregiver
Female 2154/3000 71.8% (95%CI: 70.2–73.4)
Male 843/3000 28.1% (95% CI: 26.5–29.7)
Knowledge
Knowledge of Pap Smear tests 786/2913 27% (95%CI: 25.4–28.6)
HPV knowledge among caregivers 824/2853 28.90% (95%CI:.27.2–30.6)
Female caregiver having had cytological screening 307/ 2126 14.40% (95%CI: 13.0–16.0)
Vaccines
Childhood vaccines 2808/ 2994 93.80% (95%CI: 92.9–.94.6)
HPV second dose 1933/ 3026 63.80% (95%CI: 62.13–65.6)
HPV third dose 1182/ 3026 39.10% (95%CI: 37.3–40. 8)
Mean time between second HPV dose and first dose 33 days (SD 22.7)
Mean time between third HPV dose and second dose 148 days (SD: 17.5)
Median time elapsed between first and last HPV dose 175 days (IQR: 168–182)
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This research builds on limited research in Kenya on
HPV vaccine acceptability for young girls and sought to
explore factors associated with administration of the
HPV vaccine, which is to our knowledge the first study
to explore bottlenecks and facilitators for receiving 2
or 3 doses of HPV vaccine regimen. We have a vac-
cine uptake of 64% of two doses compared with other
countries with less than 50%. Kenya is considering a
national HPV vaccine program through GAVI after a
successful pilot in 2015.
Our study revealed that only about 40% of school girls
who had a first HPV dose got the third dose. Our low
full uptake findings echo in Becker-Drep’s study et al.
[15] on HPV vaccine acceptability among Kenya women,
where women expressed a strong preference for a
vaccine that would require only one dose as opposed
to a vaccine requiring three doses [15]. In malaria en-
demic settings like Western Kenya, uptake of three
doses may be negatively affected hence the need for
more studies on the effect of malaria on long term
vaccine protection and dosing.
Our very strong statistically significant association ob-
served between administration of the second HPV dose
and third HPV dose within the six-month time period
that was initially stipulated by the WHO before the 2
dose regimen was introduced in 2014 suggests that
the majority of guardians who are favourable to a sec-
ond dose of HPV vaccine are willing and also under-
stand the necessity of having their daughters receive a
third HPV dose.
Vermandere et al. qualitative study on implementation
of HPV vaccine program in Eldoret in Eldoret by key
stakeholders showed that caretakers and teachers poorly
understood cervical cancer and linked it with modern
lifestyle and nonconforming sexual behavior. And few
had ever heard about the vaccination opportunity and
felt uncomfortable to discuss cervical cancer. Teachers
needed support from health care workers to address
questions from parents and there was distrust towards
HPV vaccines [33].
Masika et al. [34] found out that knowledge about
HPV vaccine among school teachers was low to moder-
ate but high vaccine acceptability hence may affect up-
take. Empowering teachers to be vaccine champions in
their community may be a feasible way of disseminating
information about HPV vaccine and cervical cancer [34].
Distance was found to be a significant predictor of
HPV vaccine uptake, which suggests that a different vac-
cine delivery strategy be envisaged. This observation also
concurs with Vermandere et al. (2012) observations that
acceptability of the HPV vaccine may not translate in
higher HPV uptake, lest operational problems are
addressed for parents.
As expected since the outcomes of interest were facili-
tators and barriers for HPV protection after 1st dose
and not uptake of the first dose, it was anticipated that
no significant association would then be found between
Christian and Muslim religion. With less than 1% of the
study population reporting a religion other Christianity,
we expected a slightly higher percentage given that the
Muslim population in our study setting is close to 10%
further studies should be conducted to find out any rela-
tionship between religion and vaccine acceptability and
uptake.
Intuitively, we would have expected female parents/
guardians to be significant predictor of three dose vac-
cine administration; however our results show that male
parent/guardians were significantly associated with three
dose regimen administration.
Also, whilst we observed a strong association between
HPV knowledge and HPV vaccine uptake, unexpectedly,
no statistically significant association was detected with
undergoing Pap smear test by female parent/guardian,
which may be indicative of the scarcity of information
delivered to women receiving cytological screening on
the necessity of HPV vaccine uptake for cervical cancer
prevention.
Strength and limitations
The study’s strength is that is our big sample size and
that it is the first study to our knowledge that explores
facilitators and barriers for HPV vaccine regimen uptake.
However, our limitations include lack of data on poten-
tial known confounders, including meteorological condi-
tions and time used to travel to the vaccine center as
well as other potential unknown confounders which may
not have been identified.
WHO guidelines 2014 and the CDC guidelines of
2016 have recommended 2 doses of HPV vaccine to girls
less than 15 years old except those that are immuno-
compromised and HIV infected and 3 doses for those
Table 2 Barriers/facilitators of full HPV vaccine regime
Barriers/facilitators of full HPV
vaccine regimen
Odds Ratio 95% CI P value
Administration of second
dose of HPV
61.1 40.9–91.0 < 0.0001
HPV knowledge 1.2 1.1–1.5 0.008
Male guardian 1.14 1.0–1.3 0.04
Pap Smear test knowledge 1.2 1.0–1.4 0.08
Childhood vaccine 1.2 0.8–1.6 0.4
Religion 1.1 0.4–2.5 0.9
Female guardian who had
a Pap Smear test
0.9 0.7–1.2 0.6
Differences in medians
Age 0.1
Distance 0.01
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15 years and older, immunocompromised, HIV infected
and this may hamper generalizability of our findings [7].
Policy implications and research gaps
Our findings highlighting the low HPV vaccine uptake
has a number of policy implications which could be ad-
dressed within the future Kenyan National Cervical Can-
cer Prevention strategic Plan (https://www.k4health.org/
toolkits/Kenya-health-national-cervical-cancer-preven-
tion-program-strategicplan-2012-2015. The observations
derived from our study suggest that the plan could also
promote screening for women so that they subsequently
understand the importance of HPV vaccination and the
completion of the recommended dose regimen. With re-
search ongoing with respect to one dose HPV, implica-
tions on HIV, malaria/helminth infestation should be
taken into consideration.
As distance to the clinic was found in our study to be
a strong predictor of HPV vaccine uptake, a school-
based vaccination, which has a track record of being
more efficient [35], may be an alternative strategy pro-
viding that school attendance among girls reaches a cer-
tain threshold. Empowering teachers to be vaccine
champions in their community may be a feasible way of
disseminating information about HPV vaccine and
cervical cancer and subsequently improve uptake.
Lastly, our current lack of knowledge of operational
bottlenecks in Kenya for HPV vaccination uptake would
benefit from qualitative studies to inform future quanti-
tative survey tools. Qualitative studies are needed to illu-
minate our finding concerning why male guardians
appear to be conducive to higher uptake of the HPV vac-
cine regimen.
Conclusion
Findings from this study suggested a need to consider
school-based vaccination and more active education of
caregivers to increase attainment of HPV vaccination
regimen. Promoting screening among women so that
they, in turn be targeted by an awareness campaign on
the importance of HPV vaccination for cervical cancer
prevention.
Qualitative methods are urgently needed to illuminate
our study’s quantitative findings and to inform future
time series of cross-sectional surveys to reflect the
trends of knowledge and barriers locally.
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